Skip to content
Screener

Oruka Therapeutics, Inc. ORKA Investing Cash Flow

Investing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.61B-241%
Eli Lilly logo
Eli LillyLLY
-$15.4B-739%
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$1.11B+93.9%
Amgen logo
AmgenAMGN
-$569M-46.3%
AbbVie logo
AbbVieABBV
-$574M+21.9%
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
$98K-99.8%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.96B+1,120%
Enterprise value$5.91B+1,289%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Purchases of property and equipment(73)(13)
Purchases of marketable securities(90,834)(44,290)
Proceeds from maturities of marketable securities76,47087,169
Net cash (used in) provided by investing activities(14,437)42,866
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options and employee warrants1,698
Proceeds from at-the-market offering, net of commissions38,902
Net cash provided by financing activities40,600

Item 1. Financial Statements (Unaudited)

FAQ

What is Oruka Therapeutics, Inc.'s investing cash flow?
Oruka Therapeutics, Inc. (ORKA) reported investing cash flow of -$14.44M in Q1 2026.
How has Oruka Therapeutics, Inc.'s investing cash flow changed year-over-year?
Oruka Therapeutics, Inc.'s investing cash flow decreased by 133.7% year-over-year, from $42.87M to -$14.44M.
What is the long-term trend for Oruka Therapeutics, Inc.'s investing cash flow?
Over 2 years (2021 to 2025), Oruka Therapeutics, Inc.'s investing cash flow has grown at a 4643.3% compound annual growth rate (CAGR), from -$43K to -$96.75M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Oruka Therapeutics, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude